CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Redx Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Redx Pharma PLC
Block 33, Mereside,, Alderley Park
Phone: +44 1625469900p:+44 1625469900 MACCLESFIELD, SK10 4TG  United Kingdom Fax: +44 1517064749f:+44 1517064749
Business Summary
Redx Pharma Limited is a United Kingdom-based clinical-stage biotechnology company. It focuses on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. The Company’s pipeline includes zelasudil (RXC007), zamaporvint (RXC004) and RXC008. Its lead asset, zelasudil (RXC007), a selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and cancer-associated fibrosis, is in a Phase 2 clinical program with an initial indication in idiopathic pulmonary fibrosis. RXC008 is a potential GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease. Its oncology pipeline is led by zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy, and its drug discovery engine is advancing a pipeline of research programs and collaborations in both fibrotic diseases and oncology.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20239/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Jane V.Griffiths 66 12/1/2021 12/1/2021
Chief Executive Officer, Executive Director LisaAnson 52 6/1/2018 6/1/2018
Chief Financial Officer Peter J.Collum 5/5/2021 5/5/2021
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Redx Oncology Ltd. 17 Marble Street Manchester United Kingdom

Business Names
Business Name
Redx Anti-Infectives Limited
Redx Immunology Limited
Redx MRSA Limited
REDX Oncology Limited

General Information
Number of Employees: 101 (As of 9/30/2023)
Outstanding Shares: 388,985,916 (As of 11/7/2023)
Stock Exchange: LON
Fax Number: +44 1517064749


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, June 3, 2025